Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 09, 2021

BUY
$50.3 - $78.44 $196,320 - $306,151
3,903 Added 86.73%
8,403 $659,000
Q1 2021

May 10, 2021

BUY
$53.8 - $81.53 $242,100 - $366,885
4,500 New
4,500 $257,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.88B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Gam Holding Ag Portfolio

Follow Gam Holding Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gam Holding Ag, based on Form 13F filings with the SEC.

News

Stay updated on Gam Holding Ag with notifications on news.